Shanna L Burke1, Peter Maramaldi2,3,4, Tamara Cadet2,3, Walter Kukull5,6. 1. Robert Stempel College of Public Health and Social Work, School of Social Work, Florida International University, Miami, FL, USA. 2. Simmons College School of Social Work, Boston, MA, USA. 3. Oral Health Policy and Epidemiology, Harvard School of Dental Medicine, Boston, MA, USA. 4. Department of Social and Behavioral Sciences, Harvard T. H. Chan School of Public Health, Boston, MA, USA. 5. Department of Epidemiology, University of Washington, Seattle, WA, USA. 6. National Alzheimer's Coordinating Center, University of Washington, Seattle, WA.
Abstract
OBJECTIVE: Alzheimer's disease (AD) is a neurodegenerative disease, manifesting in clinically observable deficits in memory, thinking, and behavior that disproportionately affects older adults. Susceptibility genes, such as apolipoprotein ε4, have long been associated with an increased risk of AD diagnosis. Studies have shown associations between depression and increased risk of AD development. Furthermore, findings from previous investigations suggest mixed effects in the use of psychotropic medication in older adults. The hypothesis for this study is that antidepressant use modifies the increased hazard of depression or such that a non-significant hazard will result with respect to eventual AD development. METHODS: Utilizing data from the National Alzheimer's Coordinating Center, we examined evaluations of 11,443 cognitively intact participants. Survival analysis was used to explore relationships between depression, apolipoprotein E, AD diagnosis, and antidepressant use. RESULTS: An analytical sample of 8732 participants with normal cognition was examined. Among users of antidepressant medication, the hazard, in most cases, was no longer statistically significant. One generic medication showed protective benefits for users (p < 0.001). In addition, there was a statistically significant relationship between recent depression (n = 2083; p < 0.001), lifetime depression (n = 2068; p < 0.05), and ε4 carrier status (n = 2470; p < 0.001) and AD development. CONCLUSIONS: The findings suggest that a mechanism related to antidepressant use may reduce the hazard of eventual AD. Furthermore, the findings reinforce the association between depression, apolipoprotein E (APOE) ε4, and AD diagnosis. This study contributes to the emerging literature exploring interventions aimed at decreasing the risk of AD by targeting potentially modifiable psychosocial risk factors such as depression.
OBJECTIVE:Alzheimer's disease (AD) is a neurodegenerative disease, manifesting in clinically observable deficits in memory, thinking, and behavior that disproportionately affects older adults. Susceptibility genes, such as apolipoprotein ε4, have long been associated with an increased risk of AD diagnosis. Studies have shown associations between depression and increased risk of AD development. Furthermore, findings from previous investigations suggest mixed effects in the use of psychotropic medication in older adults. The hypothesis for this study is that antidepressant use modifies the increased hazard of depression or such that a non-significant hazard will result with respect to eventual AD development. METHODS: Utilizing data from the National Alzheimer's Coordinating Center, we examined evaluations of 11,443 cognitively intact participants. Survival analysis was used to explore relationships between depression, apolipoprotein E, AD diagnosis, and antidepressant use. RESULTS: An analytical sample of 8732 participants with normal cognition was examined. Among users of antidepressant medication, the hazard, in most cases, was no longer statistically significant. One generic medication showed protective benefits for users (p < 0.001). In addition, there was a statistically significant relationship between recent depression (n = 2083; p < 0.001), lifetime depression (n = 2068; p < 0.05), and ε4 carrier status (n = 2470; p < 0.001) and AD development. CONCLUSIONS: The findings suggest that a mechanism related to antidepressant use may reduce the hazard of eventual AD. Furthermore, the findings reinforce the association between depression, apolipoprotein E (APOE) ε4, and AD diagnosis. This study contributes to the emerging literature exploring interventions aimed at decreasing the risk of AD by targeting potentially modifiable psychosocial risk factors such as depression.
Authors: Guy M McKhann; David S Knopman; Howard Chertkow; Bradley T Hyman; Clifford R Jack; Claudia H Kawas; William E Klunk; Walter J Koroshetz; Jennifer J Manly; Richard Mayeux; Richard C Mohs; John C Morris; Martin N Rossor; Philip Scheltens; Maria C Carrillo; Bill Thies; Sandra Weintraub; Creighton H Phelps Journal: Alzheimers Dement Date: 2011-04-21 Impact factor: 21.566
Authors: P B Rosenberg; M M Mielke; D Han; J S Leoutsakos; C G Lyketsos; P V Rabins; P P Zandi; J C S Breitner; M C Norton; K A Welsh-Bohmer; I H Zuckerman; G B Rattinger; R C Green; C Corcoran; J T Tschanz Journal: Int J Geriatr Psychiatry Date: 2012-02-29 Impact factor: 3.485
Authors: Joseph M Castellano; Jungsu Kim; Floy R Stewart; Hong Jiang; Ronald B DeMattos; Bruce W Patterson; Anne M Fagan; John C Morris; Kwasi G Mawuenyega; Carlos Cruchaga; Alison M Goate; Kelly R Bales; Steven M Paul; Randall J Bateman; David M Holtzman Journal: Sci Transl Med Date: 2011-06-29 Impact factor: 17.956
Authors: John R Cirrito; Brianne M Disabato; Jessica L Restivo; Deborah K Verges; Whitney D Goebel; Anshul Sathyan; Davinder Hayreh; Gina D'Angelo; Tammie Benzinger; Hyejin Yoon; Jungsu Kim; John C Morris; Mark A Mintun; Yvette I Sheline Journal: Proc Natl Acad Sci U S A Date: 2011-08-22 Impact factor: 11.205
Authors: Ingmar Skoog; Margda Waern; Paul Duberstein; Kaj Blennow; Henrik Zetterberg; Anne Börjesson-Hanson; Svante Östling; Xinxin Guo; Jürgen Kern; Deborah Gustafson; Pia Gudmundsson; Thomas Marlow; Silke Kern Journal: Biol Psychiatry Date: 2015-01-29 Impact factor: 13.382
Authors: Mitzi M Gonzales; Jasmeet Samra; Adrienne O'Donnell; R Scott Mackin; Joel Salinas; Mini E Jacob; Claudia L Satizabal; Hugo J Aparicio; Emma G Thibault; Justin S Sanchez; Rebecca Finney; Zoe B Rubinstein; Danielle V Mayblyum; Ron J Killiany; Charlie S Decarli; Keith A Johnson; Alexa S Beiser; Sudha Seshadri Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Martina Svensson; Gustaf Olsson; Yiyi Yang; Sara Bachiller; Maria Ekemohn; Joakim Ekstrand; Tomas Deierborg Journal: Sci Rep Date: 2021-03-01 Impact factor: 4.379
Authors: Lilah Besser; Walter Kukull; David S Knopman; Helena Chui; Douglas Galasko; Sandra Weintraub; Gregory Jicha; Cynthia Carlsson; Jeffrey Burns; Joseph Quinn; Robert A Sweet; Katya Rascovsky; Merilee Teylan; Duane Beekly; George Thomas; Mark Bollenbeck; Sarah Monsell; Charles Mock; Xiao Hua Zhou; Nicole Thomas; Elizabeth Robichaud; Margaret Dean; Janene Hubbard; Mary Jacka; Kristen Schwabe-Fry; Joylee Wu; Creighton Phelps; John C Morris Journal: Alzheimer Dis Assoc Disord Date: 2018 Oct-Dec Impact factor: 2.703